476 related articles for article (PubMed ID: 26068539)
21. Clinical relevance of pharmacokinetic and pharmacodynamic properties of edoxaban when treating patients with atrial fibrillation and heart failure.
Aspromonte N; Colivicchi F
Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):113-122. PubMed ID: 27819149
[TBL] [Abstract][Full Text] [Related]
22. Safety and efficacy of edoxaban, an oral factor xa inhibitor, for thromboprophylaxis after total hip arthroplasty in Japan and Taiwan.
Fuji T; Wang CJ; Fujita S; Kawai Y; Kimura T; Tachibana S
J Arthroplasty; 2014 Dec; 29(12):2439-46. PubMed ID: 25047458
[TBL] [Abstract][Full Text] [Related]
23. Edoxaban in venous thromboembolism and stroke prevention: an appraisal.
Proietti M; Lip GY
Vasc Health Risk Manag; 2016; 12():45-51. PubMed ID: 27013883
[TBL] [Abstract][Full Text] [Related]
24. The factor xa inhibitor edoxaban for the prevention of stroke and systemic embolism in patients with atrial fibrillation.
Minguet J; Sims HM; Smith KH; Bramlage P
Expert Rev Clin Pharmacol; 2017 Jan; 10(1):5-15. PubMed ID: 27817212
[TBL] [Abstract][Full Text] [Related]
25. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
[TBL] [Abstract][Full Text] [Related]
26. Treatment of venous thrombosis with an oral direct factor Xa inhibitor edoxaban by single and multiple administrations in rats.
Morishima Y; Kamisato C; Honda Y
Eur J Pharmacol; 2014 Nov; 742():15-21. PubMed ID: 25179572
[TBL] [Abstract][Full Text] [Related]
27. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
[TBL] [Abstract][Full Text] [Related]
28. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MP; Cohen AT; Meyer G; Grosso MA; Raskob G; Weitz JI; Zhang G; Buller H
Thromb Haemost; 2016 Sep; 116(4):747-53. PubMed ID: 27440518
[TBL] [Abstract][Full Text] [Related]
29. [Edoxaban for stroke prevention in atrial fibrillation and treatment of venous thromboembolism: an expert position paper].
Weiss TW; Rohla M; Dieplinger B; Domanovits H; Fries D; Vosko MR; Gary T; Ay C
Wien Med Wochenschr; 2018 Apr; 168(5-6):133-143. PubMed ID: 28236004
[TBL] [Abstract][Full Text] [Related]
30. Characterisation of exposure versus response of edoxaban in patients undergoing total hip replacement surgery.
Rohatagi S; Mendell J; Kastrissios H; Green M; Shi M; Patel I; Salazar DE
Thromb Haemost; 2012 Nov; 108(5):887-95. PubMed ID: 23014669
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Preblick R; Kwong WJ; White RH; Goldhaber SZ
Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
[TBL] [Abstract][Full Text] [Related]
32. Edoxaban, a Novel Oral Factor Xa Inhibitor.
Minor C; Tellor KB; Armbruster AL
Ann Pharmacother; 2015 Jul; 49(7):843-50. PubMed ID: 25855704
[TBL] [Abstract][Full Text] [Related]
33. Edoxaban in patients with atrial fibrillation.
Eisen A; Ruff CT
Ther Adv Cardiovasc Dis; 2017 Mar; 11(3):81-90. PubMed ID: 26680560
[TBL] [Abstract][Full Text] [Related]
34. Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?
Gibson CM; Finks SW
Am J Med; 2017 Aug; 130(8):900-906. PubMed ID: 28390791
[TBL] [Abstract][Full Text] [Related]
35. Edoxaban for the management of elderly Japanese patients with atrial fibrillation ineligible for standard oral anticoagulant therapies: Rationale and design of the ELDERCARE-AF study.
Okumura K; Lip GYH; Akao M; Tanizawa K; Fukuzawa M; Abe K; Akishita M; Yamashita T
Am Heart J; 2017 Dec; 194():99-106. PubMed ID: 29223441
[TBL] [Abstract][Full Text] [Related]
36. Mortality in Patients with Atrial Fibrillation Randomized to Edoxaban or Warfarin: Insights from the ENGAGE AF-TIMI 48 Trial.
Giugliano RP; Ruff CT; Wiviott SD; Nordio F; Murphy SA; Kappelhof JA; Shi M; Mercuri MF; Antman EM; Braunwald E
Am J Med; 2016 Aug; 129(8):850-857.e2. PubMed ID: 26994510
[TBL] [Abstract][Full Text] [Related]
37. Genetics and the clinical response to warfarin and edoxaban: findings from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Mega JL; Walker JR; Ruff CT; Vandell AG; Nordio F; Deenadayalu N; Murphy SA; Lee J; Mercuri MF; Giugliano RP; Antman EM; Braunwald E; Sabatine MS
Lancet; 2015 Jun; 385(9984):2280-7. PubMed ID: 25769357
[TBL] [Abstract][Full Text] [Related]
38. Edoxaban: Review of pharmacology and key phase I to III clinical trials.
Plitt A; Giugliano RP
J Cardiovasc Pharmacol Ther; 2014 Sep; 19(5):409-16. PubMed ID: 24607764
[TBL] [Abstract][Full Text] [Related]
39. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
[TBL] [Abstract][Full Text] [Related]
40. Edoxaban Management in Diagnostic and Therapeutic Procedures (EMIT-AF/VTE)-Trial design.
Colonna P; von Heymann C; Santamaria A; Matsushita Y; Unverdorben M
Clin Cardiol; 2018 Sep; 41(9):1123-1129. PubMed ID: 30069910
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]